Female Sexual Medicine

Lauren Harrington, MD FACOG
Assistant Professor
Associate Division Chief
Co-director, Sexual Health Consultation Service
Medical Director, CU Central Park OB/GYN Clinic
Division of Academic Specialists in OB/GYN
University of Colorado Anschutz Medical Campus

February 22, 2024, 7:55 – 8:35 AM

1

Conflict of Interest Disclosure

None

2

Learning Objectives



- 1. Describe the **diagnostic criteria** and **etiologies** for common sexual function concerns in females.
- 2. Recommend **treatments** for common sexual function concerns.
- 3. Discuss **medications** used to support sexual function, with an emphasis on mechanism of action, side effects and clinical utility.

Acknowledgements

- Sexual health care historically and currently operates in gender binaries, heteronormative systems, and tends to cater care to those who identify as heterosexual and cisgender within monogamous relationships.
 - Restrictive binaries in DSM language
 - Lack of meaningful research of diverse gender and sexual groups
 - References to partnerships, and omission of ethically non-monogamous relationships/polyamorous relationships, and other types of sexual engagement
 - Women's Sexual Health Clinics

4

"'In high-quality health-care provision, sexual health should be integrated with all aspects of patient [...] care and should hold equal status with physical, spiritual, social, and emotional care.' ¹ Thus, it should be as natural to ask about sexual orientation as it is to ask about bowel habits." ² MARGARET R.H. NUSBAUM, D.O., M.P.H., AND CAROL D. HAMILTON, ED.D., P.A.-C.


5

Taking a Sexual History


- - Medication side effect
 Associated with longevity
 Your patients want you to
 - If not you... who?!
- Barriers
- Embarrassment
- Ill-prepared
 Not relevant



tri II, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol 2008; 112: 970–8 aum MR, Hamilton CD. The proactive sexual health history. Am Fam Physician 2002; 66: 1705–12.



Female Sexual Function Index (FSFI) • 6 domains: • Desire • Arousal • Lubrication • Orgasm • Satisfaction • Pain • Composite score: 0 – 36 • Score 226.55 = Female sexual dysfunction • Score 226.55 = Female sexual dysfunction



Sexual Interest and Arousal Disorder



- Lack of / decrease in ≥ 3 of the following:
 - Interest in sexual activity
 - Sexual or erotic thoughts / fantasies
 - Initiation of sexual activity / responsiveness to partner's initiation
 - Excitement or pleasure during (almost) all sexual activity
 - Interest or arousal in response to sexual or erotic cues (e.g. written, visual)
 - · Genital or non-genital sensations during sexual activity
- ≥6 months
- Distress

_

10

Spontaneous Desire

- Desire that seems to erupt out of nowhere
- Urge precedes sexual activity
- Desire starts in the mind
- Type of desire you often see on TV / movies
- Normal and healthy




11

Responsive Desire

- Desire that occurs in context of consensual sexual play, touch, conversation, flirtation, reading, watching
- Urge starts after stimulation
- Intentional, gradual desire
- Pathologized incorrectly as low desire
- Normal and healthy



Nagoski, E. (2015). Come as you are: the surprising new science that will transform your sex life. New York, Simon & Schuster Paperbacks.



Female Orgasmic Disorder



- Orgasm that is
 - Absent
 - Delayed
 - Infrequent
 - Reduced intensity
- >6 months
- Distress

13

Female Orgasmic Disorder







- Often acquired

 Cilitaral adhesions / phimosis (GSM, lichen sclerosus)

 Neurologic condition

 latragenic: pelvic surgery, radiation

 FGM

 Psychosocial: trauma, shame, anxiety

 A sil bernovers tobus of the Peadonce and Risk Tactors of Clisual Adhesions 5.

14

Genitopelvic Pain and Penetration Disorder



- Persistent / recurrent presence of ≥ 1 during activity:
 - Vulvovaginal or pelvic pain
 - Fear / anxiety about pain
 - Tensing or tightening of pelvic floor muscles
 - Difficulty with penetration
- >6 months
- Distress

Genitopelvic Pain and Penetration Disorder



Common causes:

- High tone pelvic floor myalgia
- Genitourinary syndrome of menopause
- Trauma
- Endometriosis
- Vulvodynia
- Vulvar dermatoses

16

Substance/Medication-Induced Dysfunction



- Disturbance in sexual function
- Temporal correlation with:
 - Substance / medication initiation or discontinuation
 - Dose increase
- Distress

17

Substance/Medication-Induced Dysfunction



- Hormonal
- Psychiatric medications
- Anticholinergic
- Cardiovascular
- Alcohol, marijuana, narcotics

Other: Peripartum, Menopause

- Peripartum
 Obstetric laceration
 Lactational hypoestrogenism
 - Postpartum mood disorders
 Intimate partner violence

 - Sleep deprivation
 Relationship strain

 - Stress
 Body image
- Genitourinary Syndrome of Menopause
 Vaginal dryness, burning, irritation
- Decreased lubrication





Other: Mental Health

- Depression
 - Anhedonia
 - Avolitional
- Anxiety
 - · Anxious rumination
 - Perfectionistic expectations
- ADHD
 - · Focus, motivation
- Post-traumatic stress, childhood maltreatment/neglect
 Power and consent

 - Pleasure and the body



20


Other: Psychosocial Factors

- Sexual/relational factors
 - Partner sexual dysfunction
 Lack of novelty/repetition
 - Poor attention/focus on sexual
 - stimulation

 Pain or diminished arousal
 - Partner sexual awkwardness
- Cultural/Relational factors
- Attachment styles
 Religious/cultural/familial values, beliefs,
- Relational Discord
 Partner Psychiatric Issues
- Secondary to medical issues
 Infertility
 Changes to body
 image/mobility/accessibility



1	4
,	



22


Exam

Test for dysesthesia on:

- Inner thigh
- Labia majora
- Interlabial sulcus
- Vestibule
- Clitoris



23



Treatment

Moving beyond....


"Have a glass of wine or two to relax."

"Go on vacation."

"This is what happens after you've been partnered for 15 years."

"Biology didn't intend for females to be sexually active after menopause."

25



26

Treatment: Interest/Arousal Disorder • Psychological therapy • Mindfulness therapy • Cognitive behavioral therapy • Sex therapy • Exercise



28

Treatment: Interest/Arousal Disorder Flibanserin "Addyi" • FDA approved in 2015 for pre-menopausal women. • Post-synaptic SHT1A receptor agonist and 5HT2A receptor antagonist. • Lowers serotonin and raises dopamine and norepinephrine in prefrontal cortex. • Increases excitation, decreases inhibition • Average of one additional satisfying sexual event per month. • Daily qHS dosing. 8 week trial. • Side effects: Dizziness, somnolence, nausea, fatigue. • EtOH: Walt 2hr after EtOH. • Boxed warning. • High cost, variable insurance coverage. PhilRx.

29

Treatment: Interest/Arousal Disorder Bremelanotide "Vyleesi" • FDA approved in 2019 for pre-menopausal women. • Melanocortin receptor agonist. • Use PRN (subcutaneous injection). • Works within 45 min, and lasts 8-10 hours • Safe to use with ETOH • Side effects: Nausea. Rx with Zofran.

Treatment: Interest/Arousal Disorder

Buproprion "Wellbutrin"

- Off-label (no FDA approval).
 Consider as adjunct therapy for women with SSRI-induced low desire.

- Increases norepinephrine and dopamine.
- Reliable insurance coverage, low cost.



31

Treatment: Interest/Arousal Disorder

Post-menopausal women

- Flibanserin or Bremelanotide "off-label"
- Systemic estrogen therapy (low dose, transdermal)
- Systemic testosterone therapy (low dose, transdermal)





32

Treatment: Female Orgasmic Disorder

- Lysis of clitoral adhesions
- Pelvic floor PT
- Psychotherapy, sex therapy, sex skills training

 - Mindfulness
 Pleasure mapping



Treatment: Genitopelvic Pain & Penetration Disorder

- Pelvic floor PT
 - Myofascial release of muscle tension in pelvic floor, thighs, and abdomen
 - Biofeedback
- Dilators
 - Re-train the muscles not to contract with something in the vagina!
- Trigger point injections
- Muscle relaxants (systemic or local)
- Neuromodulators (systemic or local)
- · Pain desensitization through therapy



34

Treatment: Genitopelvic Pain & Penetration Disorder

Address comorbid conditions:

- Low estrogen
 - Menopause OR breastfeeding
 - <u>Vaginal estrogen</u> is VERY effective and LOW risk.
 - Vaginal DHEA / prasterone

Revaree Replens



35

To learn more....



- International Society for Study of Women's Sexual Health (ISSWSH)
- - Come As You Are by Emily Nagoski
 When Sex Hurts by Irwin and Andrew Goldstein & Caroline Pukall
- Mindfulness for Better Sex by Lori Brotto
- You are Not Broken Podcast by Kelly Casperson, MD
- Rosy App
- Websites:
 - OMGYes.com
 - Prosayla.com (ISSWSH patient-facing website)

Sexual Problem Assessment

- Nature of the problem
- Phases of sexual response affected and pain
- Single vs. combined (sequence)
- Lifelong vs. acquired (timeline)
- Generalized vs. situational
- Sudden vs. gradual (predisposing, precipitating, maintaining factors)
 Inhibition, performance anxiety
- Inhibition, performance anxiety, anger

2022 International Society for the Study of Women's Sexual Health, Inc

- Stimulation (technique, satisfaction)
- Contributing factors (psychological, biological, socio-cultural, relational, lifecycle)
- Depression, anxiety, trauma, substances
- Impact and distress
- \bullet Exacerbating and alleviating factors
- Partner response/sexual function, communication
- Treatments and their efficacy
- Motivation for therapy (why now?)



37

alidated Tools	
Validate Tool	Assessment Area
Decreased Sexual Desire Screener (DSDS)	Brief diagnostic tool for Hypoactive Sexual Desire Disorder (HSDD)
Female Sexual Function Index (FSFI)*	Desire, arousal, orgasm, pain
Female Sexual Distress Scale-Revised (FSDS-R)	Distress
ional Society for the Study of Women's Sexual Health, Ir	ic.